Science and Technology
CPR builds on the proprietary antibody engineering technology developed by the Chugai Group in order to achieve our goals.
ESG at Chugai Group
Chugai Group conducts its business activities to fulfill its mission of benefiting the medical community and human health around the world.
Browse through the latest news and developments by CPR and the Chugai Group.
- Chugai Reached Agreement with Japanese Government regarding Investigational Antibody Cocktail (casirivimab and imdevimab) for COVID-19
- Chugai Discontinues Marketing of Photodynamic Diagnostic Agent "ALAGLIO® Divided Granules 1.5g"
- Research Collaboration by Chugai, the University of Tokyo and RIKEN on Functional Genome Database Published in Cell